GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dermapharm Holding SE (XTER:DMP) » Definitions » Beneish M-Score

Dermapharm Holding SE (XTER:DMP) Beneish M-Score : -2.86 (As of Dec. 13, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Dermapharm Holding SE Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.86 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Dermapharm Holding SE's Beneish M-Score or its related term are showing as below:

XTER:DMP' s Beneish M-Score Range Over the Past 10 Years
Min: -3.55   Med: -2.57   Max: -2.06
Current: -2.86

During the past 11 years, the highest Beneish M-Score of Dermapharm Holding SE was -2.06. The lowest was -3.55. And the median was -2.57.


Dermapharm Holding SE Beneish M-Score Historical Data

The historical data trend for Dermapharm Holding SE's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermapharm Holding SE Beneish M-Score Chart

Dermapharm Holding SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.06 -2.57 -2.39 -2.74 -2.86

Dermapharm Holding SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -2.86 - - -

Competitive Comparison of Dermapharm Holding SE's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermapharm Holding SE's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Dermapharm Holding SE's Beneish M-Score falls into.



Dermapharm Holding SE Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Dermapharm Holding SE for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8553+0.528 * 1.018+0.404 * 1.2006+0.892 * 1.1079+0.115 * 1.2583
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2885+4.679 * -0.072688-0.327 * 1.2179
=-2.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was €95 Mil.
Revenue was €1,135 Mil.
Gross Profit was €719 Mil.
Total Current Assets was €630 Mil.
Total Assets was €2,161 Mil.
Property, Plant and Equipment(Net PPE) was €331 Mil.
Depreciation, Depletion and Amortization(DDA) was €102 Mil.
Selling, General, & Admin. Expense(SGA) was €95 Mil.
Total Current Liabilities was €394 Mil.
Long-Term Debt & Capital Lease Obligation was €964 Mil.
Net Income was €62 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €219 Mil.
Total Receivables was €100 Mil.
Revenue was €1,025 Mil.
Gross Profit was €661 Mil.
Total Current Assets was €534 Mil.
Total Assets was €1,413 Mil.
Property, Plant and Equipment(Net PPE) was €226 Mil.
Depreciation, Depletion and Amortization(DDA) was €95 Mil.
Selling, General, & Admin. Expense(SGA) was €67 Mil.
Total Current Liabilities was €218 Mil.
Long-Term Debt & Capital Lease Obligation was €512 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(94.896 / 1135.351) / (100.149 / 1024.776)
=0.083583 / 0.097728
=0.8553

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(660.833 / 1024.776) / (719.16 / 1135.351)
=0.644856 / 0.633425
=1.018

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (630.496 + 330.771) / 2160.673) / (1 - (533.947 + 225.673) / 1412.836)
=0.555108 / 0.462344
=1.2006

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1135.351 / 1024.776
=1.1079

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(94.909 / (94.909 + 225.673)) / (101.772 / (101.772 + 330.771))
=0.296052 / 0.235288
=1.2583

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(95.283 / 1135.351) / (66.748 / 1024.776)
=0.083924 / 0.065134
=1.2885

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((963.958 + 394.489) / 2160.673) / ((511.561 + 217.792) / 1412.836)
=0.628715 / 0.516233
=1.2179

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(62.368 - 0 - 219.422) / 2160.673
=-0.072688

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Dermapharm Holding SE has a M-score of -2.86 suggests that the company is unlikely to be a manipulator.


Dermapharm Holding SE Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Dermapharm Holding SE's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermapharm Holding SE Business Description

Traded in Other Exchanges
Address
Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts, and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing, and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals, and cosmetics products. Parallel import brands business operates under the AxiCorp brand.
Executives
Wilhelm Beier Supervisory Board
Dr. Hans-georg Feldmeier Board of Directors
Christof Dreibholz Board of Directors
Lothar Lanz Supervisory Board
Anja Schorn Board Member Themis Beteiligungs-AG
Hilde Neumeyer Board of Directors

Dermapharm Holding SE Headlines

No Headlines